Macrolide Antibiotics Market Information: By Drugs (Azithromycin, Clarithromycin, Erythromycin, Fidaxomicin and Telithromycin), Route of Administration (Oral, Parenteral), Indication (Infection Due to Mycoplasma Pneumoniae, Legionella Sp, or Bordetella Pertussis, Symptomatic Cat-Scratch Disease, Bacillary Angiomatosis, Peliosis Hepatis in Patients with AIDS, Cerebral Toxoplasmosis, Uncomplicated Skin Infections, others), End User (Hospitals, Dermatology Clinics, Pharmaceutical Companies, others) - Forecast till 2027
ID: MRFR/Pharma/2956-HCR | February 2021 | Region: Global | 200 pages
Macrolide Antibiotics Market Scenario
Macrolides are a class of antibiotics derived from Saccharopolyspora erythraea. They inhibit protein synthesis in bacteria by binding to the 50S ribosomal element and effective against gram positive bacteria and intracellular pathogens such as Legionella, Mycoplasma, and Chlamydia. It primarily act as a bacteriostatic agent against many strains of Corynebacteria, Listeria, Moxicella, Streptococci, Neisseria meningitides, Staphylococci, Clostridia, and Haemophilus sp.
The macrolide antibiotics market exhibits a significant growth across the globe owing to the increasing prevalence of skin infections and growing demand for drugs against bacterial skin infections.
Major concerns involved in the use of macrolide antibiotics are GI disturbances and inhibition of hepatic metabolism. According to a study published in the Journal of the American College of Cardiology, macrolide antibiotics may increase the risk of sudden cardiac death, ventricular tachyarrhythmias, and cardiovascular death in patients, which may hinder the growth of the macrolide antibiotics market over the review period.
The macrolide antibiotics market is expected to grow at a CAGR of 12.5% during the forecast period from 2017-2023.
FIGURE 1 Global Macrolide Antibiotics Market, By Region, 2016 (%) 
Key Players in the Macrolide antibiotics Market
Some of the key players in macrolide antibiotics market are Merck Sharp & Dohme Corp (U.S.), Pfizer Inc. (U.S.), Neo Química (Brazil), Macrolide Pharmaceuticals (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Fresenius Kabi USA (U.S.), Sandoz International GmbH (Germany), Gland Pharma Limited (India), Mylan N.V. (U.S.),and WOCKHARDT (U.S.)
Segments
The macrolide antibiotics market is segmented on the basis of drugs which includes azithromycin, clarithromycin, erythromycin, fidaxomicin, and telithromycin.
On the basis of route of administration, the macrolide antibiotics market is segmented into oral and parenteral.
On the basis of indication, the macrolide antibiotics market is segmented into infection due to mycoplasma pneumoniae, legionella sp, or bordetella pertussis, symptomatic cat-scratch disease, bacillary angiomatosis, peliosis hepatis in patients with AIDS, cerebral toxoplasmosis, uncomplicated skin infections, and others.
On the basis of end user, the macrolide antibiotics market is segmented into hospitals, dermatology clinics, pharmaceutical companies, and others.
Research Methodology
Regional Analysis of the Macrolide Antibiotics Market
The American region accounted for the largest share of the macrolide antibiotics market due to increasing prevalence of skin infections, and presence of prominent market players. The prevalence of bacterial skin infection increasing in the US from the last few years. Also, the number of visits to the emergency department has increased. Furthermore, increasing dose of antibiotics in number of out-patient settings in the U.S, which will drive the growth of the macrolide antibiotics market over the forecast period.
Europe is the second largest market that holds a noticeable share of the macrolide antibiotics market. In France, prevalence of symptomatic cat-scratch disease has been increasing from the last few years.
In Asia Pacific, prevalence of skin disease is found to be increasing in Japan. Rising prevalence of skin diseases, and growing awareness about the use of macrolides for the treatment of uncomplicated skin infections drives the macrolide antibiotics market in Asia Pacific.
The Middle East and Africa show steady growth in the macrolide antibiotics market.
Intended Audience
- Pharmaceutical Companies
- Medical Research Laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size | 2027: Significant Value |
| CAGR | 12.5% (2017-2023) |
| Base Year | 2019 |
| Forecast Period | 2020-2027 |
| Historical Data | 2018 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Drugs, Route of administration, Indication, End User |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Merck Sharp & Dohme Corp (U.S.), Pfizer Inc. (U.S.), Neo Química (Brazil), Macrolide Pharmaceuticals (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Fresenius Kabi USA (U.S.), Sandoz International GmbH (Germany), Gland Pharma Limited (India), Mylan N.V. (U.S.),and WOCKHARDT (U.S.) |
| Key Market Opportunities | New product launches and R&D Amongst major key Players |
| Key Market Drivers |
|
Brief TOC
1 Report Prologue
2 Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3 Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
4 Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
5. Market Factor Analysis
5.1 Porters five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain
5.3 Investment Feasibility Analysis
5.4 Price Factor Analysis
6. Global Macrolide Antibiotics Market, by Drug
6.1 Introduction
6.2 Azithromycin
6.3 Clarithromycin
6.4 Erythromycin
6.5 Fidaxomicin
6.6 Telithromycin
7. Global Macrolide Antibiotics Market, by Route of Administration
7.1 Introduction
7.2 Infection Due to Mycoplasma Pneumonia, Legionella Sp, or Bordetella pertussis
7.3 Symptomatic Cat-scratch Disease
7.4 Bacillary Angiomatosis
7.5 Peliosis Hepatis in Patients with AIDS
7.6 Cerebral Toxoplasmosis
7.7 Uncomplicated Skin Infections
7.8 Others
7.8.1 Babesiosis
7.8.2 Chlamydia Trachomatis Urethritis and Cervicitis
8. Global Macrolide Antibiotics Market, by End User
8.1 Introduction
8.2 Hospitals
8.3 Dermatology Clinics
8.4 Pharmaceutical Companies
8.5 Others
9. Global Macrolide Antibiotics Market, by Region
9.1 Introduction
9.2 Americas
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 UK
9.3.1.4 Italy
9.3.1.5 Spain
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Republic of Korea
9.4.5 Australia
9.4.6 Rest of Asia Pacific
9.5 Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of Middle East & Africa
10 Company Landscape
10.1 Introduction
10.2 Market share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments
11 Company Profiles
11.1 Merck Sharp & Dohme Corp
11.1.1 Company Overview
11.1.2 Product Overview
11.1.3 Financials
11.1.4 SWOT Analysis
11.2 Pfizer Inc.
11.2.1 Company Overview
11.2.2 Product Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 Teva Pharmaceutical Industries Ltd.
11.3.1 Company Overview
11.3.2 Product Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 Fresenius Kabi USA
11.4.1 Company Overview
11.4.2 Product/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 Sandoz International GmbH
11.5.1 Company Overview
11.5.2 Product Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.6 Macrolide Pharmaceuticals
11.6.1 Company Overview
11.6.2 Product Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.7 Neo Química
11.7.1 Overview
11.7.2 Product Overview
11.7.3 Financials
11.7.4 Key Developments
11.7.5 SWOT Analysis
12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO’s View Point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of Healthcare Industry
13 Appendix